Takeda (4502) at 4.5% Yield: Why U.S. Investors Buy TAK

¥200 annual dividend. ¥517 Core EPS. A 38.7% payout ratio most US investors never calculate because “Japanese pharma” sounds complicated. Fifteen analysts on Minkabu now see nearly 20% upside from current prices. Here is my honest take on Takeda’s income case. — DividendDan

Disclosure: Educational content only, not investment advice. The author may or may not hold positions in stocks mentioned. See Disclaimer for FTC 16 CFR Part 255 compliant details. Last updated: May 2026.

Most US pharma income investors scan Pfizer, AbbVie, and Bristol Myers Squibb — and overlook the one global pharmaceutical company that quietly generates roughly half its revenue inside the United States.

That company is Takeda Pharmaceutical (TYO: 4502 / NYSE ADR: TAK). Its ADR trades in every US brokerage account, offers a ~3.9% gross yield at current prices, and carries pipeline upside that Japan-based analysts are pricing in at nearly 20% above current levels.

This article answers the practical questions a US investor in their 50s or 60s actually needs: What is the real yield after FX and withholding? Can I hold TAK in an IRA? And is the ¥200 dividend safe?

Metric	Value
Stock Price (JPY)	¥5,118 (May 2026)
Annual Dividend (JPY)	¥200 per share
Dividend Yield	~3.9% at ¥5,118 (entry near ¥4,444 yielded ~4.5%)
Core EPS (FY2025)	¥517 — payout ratio 38.7%
Reported EPS (FY2025)	¥122 (inflated by non-cash Shire amortization)
P/E Ratio (TTM)	~44x (reported)
Market Cap	¥8.14 trillion
52-Week Range	¥4,086 – ¥6,033
US ADR Ticker	TAK (NYSE); 1 ADR = 0.5 ordinary shares

Why Takeda Stands Out Among Global Pharma Income Plays

Takeda’s 2019 acquisition of Shire transformed it into a genuinely global company. Roughly 50% of revenue now comes from the United States; Japan accounts for under 20%.

According to Takeda’s Annual Report (IR page), five core therapy areas — oncology, rare diseases, neuroscience, gastroenterology, and plasma-derived therapies — account for over 80% of total revenue.

That geographic spread matters for dividend sustainability. No single country’s pricing pressure or regulatory change can topple Takeda’s revenue base on its own.

For US investors comparing pharma income options, Takeda’s ~3.9% yield still compares favorably to Johnson & Johnson (under 3.2%). It is also more defensively covered than Pfizer’s elevated yield, which reflects deeper pipeline uncertainty than Takeda faces.

The Dividend: ¥200 Per Share and What It Means in Dollars

Takeda pays an annual dividend of ¥200 per share (FY2025, ending March 2026), raised from the prior ¥188 level. Management has signaled continued commitment to this payout as Shire debt deleveraging progresses.

The dividend is well-covered on a Core EPS basis. FY2025 Core EPS of ¥517 implies a payout ratio of just 38.7% — conservative for a large-cap global pharma.

The headline reported EPS of ¥122 looks alarming, but it reflects non-cash amortization from the Shire acquisition, not a cash earnings problem. Core Operating Profit hit ¥1,172.5 billion in FY2025, up 0.8% year-over-year.

For US ADR holders, each TAK ADR represents 0.5 ordinary shares. The annual ADR dividend is approximately ¥100, converted to USD at the prevailing exchange rate on each payment date.

At ¥150/USD, ¥100 converts to roughly $0.67 per ADR. At ¥130/USD (stronger yen), the same payment rises to approximately $0.77. A 10% yen move shifts your effective dollar yield by roughly 0.4–0.5 percentage points.

For US investors building a dividend income floor, this FX variability is real but manageable. The BOJ 主な意見（金融政策決定会合） signals gradual rate normalization, which may support a modestly stronger yen over the medium term — a tailwind for USD-denominated dividend income.

What Japanese Investors See: Minkabu Consensus

One advantage of analyzing a Tokyo-headquartered company is access to domestic Japanese analyst coverage — a data source US investors rarely reach directly.

As of May 2026, みんかぶ (Minkabu) shows a consensus of 6 Strong Buy, 4 Buy, and 5 Neutral across 15 analysts, with an average fair-value estimate of ¥6,130 — implying approximately 19.8% upside from ¥5,118.

That near-20% consensus upside from analysts who cover Takeda in Japanese and monitor domestic pipeline data suggests the market is discounting the three near-term launch products more heavily than the fundamentals justify.

Those three products — oveporexton, rusfertide, and zasocitinib — span neuroscience, rare diseases, and autoimmune indications. For a dividend investor, this domestic optimism is a meaningful signal: the ¥200 payout faces less structural pressure than the headline P/E implies.

You can track Takeda’s price action and pipeline news flow on TradingView, which supports side-by-side charting of 4502 (TSE) and TAK (NYSE ADR) in a single view.

Pipeline: Where the Upside (and Risk) Live

Takeda’s pipeline includes over 40 molecules in clinical development. According to Takeda’s pipeline disclosure page, growth and launch products already represent over 50% of total revenue and grew 4.5% at constant exchange rates in FY2025 — partially offsetting the Vyvanse revenue gap.

Vyvanse (lisdexamfetamine) lost US exclusivity in 2023. Generic erosion is now fully flowing through reported revenue. Takeda’s TDnet 適時開示 (Japanese regulatory filings) show management is managing this transition with OPEX reductions and accelerated pipeline investment.

Per Takeda’s FY2025 full-year results press release (May 2026): Revenue ¥4,505.7 billion (down 1.7% YoY at actual exchange rates); Core EPS ¥517 (up 5.2% YoY). The underlying business is holding up despite the Vyvanse headwind.

A May 2026 US antitrust verdict related to AMITIZA® prompted a separate FY2025 IFRS earnings revision — a reminder that legal overhangs can move the reported earnings line in ways that are disconnected from operating cash flow.

IRA Eligibility and US Tax Treatment

US investors frequently ask whether TAK can be held in an IRA. The answer is yes — the NYSE-listed ADR (TAK) can be held in most IRAs and standard brokerage accounts without restriction.

However, there is a meaningful tax nuance. Japan withholds 15% on dividends paid to US investors. In a taxable account, you can reclaim this via IRS Form 1116 (Foreign Tax Credit).

In a traditional IRA or Roth IRA, you generally cannot reclaim the foreign withholding. Your effective IRA yield is approximately 15% lower than the stated gross yield.

At a ~3.9% gross yield, your net IRA yield is approximately 3.3%. Still competitive versus US investment-grade bonds, but worth factoring into your asset-location strategy. Many advisors suggest holding foreign dividend payers in taxable accounts where Form 1116 credit is accessible.

Risks and Counter-View

A constructive view on Takeda requires honestly confronting three substantive risks:

1. Debt load from the Shire acquisition. Takeda took on approximately $30 billion in net debt to acquire Shire in 2019. While deleveraging has progressed, the balance sheet remains stretched. Current net debt/EBITDA ratios are available via EDINET 有価証券報告書. A severe revenue shortfall could force a dividend review.

2. Vyvanse generic erosion and ongoing legal risk. Vyvanse was Takeda’s largest single product; generics are now active in the US market. The AMITIZA antitrust verdict adds a further legal overhang. Execution risk on the three pipeline replacements is real and material.

3. Yen depreciation risk. A sustained weak yen reduces dollar-denominated dividend income for US ADR holders. While the BOJ’s rate normalization trajectory may provide some support, yen direction remains genuinely uncertain. See BOJ Outlook for Economic Activity and Prices for the current policy framework.

Investors who believe pipeline execution will disappoint, or that yen weakness persists structurally, would reasonably hold a more cautious stance on TAK at current prices.

Bottom Line — Author’s View: Constructive (Income)

Takeda is an income story with pipeline optionality layered on top — not a growth story. At ¥5,118 per ordinary share (May 2026), the ~3.9% gross yield is backed by a 38.7% Core EPS payout ratio. That is a structurally conservative dividend for a company of this global scale.

The headline 44x P/E is misleading. Strip out non-cash Shire amortization and the earnings picture normalizes considerably — Core Operating Profit grew 0.8% in FY2025 despite the Vyvanse revenue hit, and Core EPS rose 5.2% year-over-year.

The Minkabu consensus — 6 Strong Buy, 4 Buy, 5 Neutral; avg fair-value estimate ¥6,130 — reinforces that Japan-based analysts view the current price as a pipeline-discount entry, not a value trap.

For a US investor in their 50s or 60s seeking international pharma income diversification, locking in near 3.9%–4.5% (depending on entry price) while the pipeline matures is a reasonable allocation. Size it as a diversified holding, not a concentrated bet, given the debt load and FX exposure.

Frequently Asked Questions

Q: What is Takeda’s current dividend yield?

At ¥5,118 per ordinary share (May 2026), the annual ¥200 dividend implies a gross yield of approximately 3.9%. Entry near ¥4,444 — within the 52-week range — would have secured closer to 4.5%. The ADR (TAK) yield reflects the same calculation, converted to USD at the prevailing exchange rate.

Q: Can I hold Takeda (TAK) in a US IRA or 401(k)?

Yes. The NYSE-listed ADR (TAK) can be held in most IRAs and standard brokerage accounts. Japan’s 15% dividend withholding is not recoverable inside an IRA, reducing effective yield from ~3.9% to approximately 3.3%. Confirm ADR eligibility with your plan administrator.

Q: How does FX risk affect Takeda’s yield for US investors?

Takeda pays dividends in yen. Each TAK ADR represents 0.5 ordinary shares, making the approximate annual ADR dividend ¥100. At ¥150/USD that converts to ~$0.67; at ¥130/USD it rises to ~$0.77. A 10% yen move shifts your effective dollar yield by roughly 0.4–0.5 percentage points.

Q: Is the 15% Japanese withholding tax recoverable?

In a taxable account, yes — claim it as a foreign tax credit on IRS Form 1116. In a traditional IRA or Roth IRA, the withholding is generally not recoverable. Holding TAK in a taxable account is therefore the more tax-efficient approach for most US investors.

Q: Where can I find Takeda’s official Japanese-language IR disclosures?

Takeda files 決算短信 (quarterly earnings summaries) and 中期経営計画 (medium-term management plans) via TDnet（東証適時開示） and EDINET 有価証券報告書. These are the authoritative primary sources for Japanese-language financial filings.

How to Buy 4502 (TAK) from the U.S.

Takeda Pharmaceutical is listed on the Tokyo Stock Exchange as 4502 and trades as an ADR on the NYSE under the ticker TAK. Each TAK ADR represents 0.5 ordinary shares. Most US investors will find the ADR the simpler route — it settles in USD and is available through any standard US brokerage account.

International investors can access Takeda (4502 / TAK) through:

• Saxo Bank — full TSE coverage, available in Singapore, Japan, and Europe; preferred for Asia-based investors seeking direct TSE access to 4502 ordinary shares
• Interactive Brokers (IBKR) — direct TSE access, low FX spread; strong for US-based investors who prefer the Tokyo-listed shares over the ADR
• Webull — accessible for smaller US investors; TAK ADR available through a standard account
• Any major US broker (Fidelity, Schwab, Vanguard) — TAK ADR is NYSE-listed and requires no special account type

Note for US tax purposes: Japanese dividend withholding is 15%. In a taxable account, claim the foreign tax credit on IRS Form 1116. In an IRA, the withholding is generally not recoverable — factor this into your account location decision.

Primary sources for due diligence: Takeda IR (English) | TDnet 適時開示（Japanese） | EDINET 有価証券報告書（Japanese） | BOJ 主な意見（Japanese） | みんかぶ 4502 アナリスト予想（Japanese）

Account opening eligibility varies by broker and jurisdiction. I am not affiliated with any of these brokers; this is general information only.

This article is for educational purposes only and does not constitute investment advice. Opinions are my own, not investment advice. The author may or may not hold positions in securities mentioned. Per FTC 16 CFR Part 255, material connections are disclosed in our Disclaimer. Last updated: May 2026.